血小板活化因子的拮抗剂可抵消烷基溶血磷脂的杀肿瘤作用。 - Suppr

Suppr

超能文献

An antagonist to platelet activating factor counteracts the tumoricidal action of alkyl lysophospholipids.

作者信息

Bazill G W, Dexter T M

机构信息

Paterson Institute for Cancer Research, Manchester, U.K.

出版信息

Biochem Pharmacol. 1989 Jan 15;38(2):374-7. doi: 10.1016/0006-2952(89)90053-1.

DOI:10.1016/0006-2952(89)90053-1

PMID:2536543

Abstract

摘要

相似文献

An antagonist to platelet activating factor counteracts the tumoricidal action of alkyl lysophospholipids.

Biochem Pharmacol. 1989 Jan 15;38(2):374-7. doi: 10.1016/0006-2952(89)90053-1.

[Platelet-activating factor (PAF) antagonists].

Tanpakushitsu Kakusan Koso. 1991 Feb;36(3):379-87.

Platelet-activating factor (PAF) antagonist WEB 2086 does not modulate the cytotoxicity of PAF or antitumour alkyl lysophospholipids ET-18-O-methyl and SRI 62-834 in HL-60 promyelocytic leukaemia cells.

Biochem Pharmacol. 1991 Jan 15;41(2):319-22. doi: 10.1016/0006-2952(91)90496-r.

Antitumor ether lipids: endocytosis as a determinant of cellular sensitivity.

Cancer Cells. 1991 Aug;3(8):315-7.

A platelet-activating factor receptor antagonist protects against renal function deterioration in nephrotoxic nephritis.

Adv Prostaglandin Thromboxane Leukot Res. 1987;17B:828-32.

Beneficial effects of (RS)-2-methoxy-3-(octadecylcarbamoyloxy)propyl 2-(3-thiazolio)ethyl phosphate, a specific PAF antagonist, in endotoxin and anaphylactic shock.

Adv Prostaglandin Thromboxane Leukot Res. 1985;15:715-7.

A specific, photolabile and irreversible antagonist (L662,025) of the PAF-receptor.

Biochem Biophys Res Commun. 1989 May 30;161(1):23-30. doi: 10.1016/0006-291x(89)91554-4.

Species difference in the specific receptors of platelet activating factor.

Biochem Pharmacol. 1986 Dec 15;35(24):4511-8. doi: 10.1016/0006-2952(86)90772-0.

Modulation of long-term potentiation in the CA1 area of rat hippocampus by platelet-activating factor.

Adv Exp Med Biol. 1999;469:221-7. doi: 10.1007/978-1-4615-4793-8_33.

Evaluation of some benzyl and benzylidene monosubstituted gamma-butyrolactones and tetrahydrofurans as platelet activating factor antagonist agents.

Farmaco. 1995 Jul-Aug;50(7-8):511-8.

引用本文的文献

In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434.

Br J Cancer. 1993 May;67(5):989-95. doi: 10.1038/bjc.1993.181.

Cell-signaling targets for antitumour drug development.

Cancer Chemother Pharmacol. 1993;32(1):1-19. doi: 10.1007/BF00685870.

Autoradiographic localization of platelet-activating factor (PAF) binding sites in the rabbit endometrium during the peri-implantation period.

Cell Tissue Res. 1991 Aug;265(2):231-41. doi: 10.1007/BF00398071.

Is metabolism an important arbiter of anticancer activity of ether lipids? Metabolism of SRI 62-834 and hexadecylphosphocholine by [31P]-NMR spectroscopy and comparison of their cytotoxicities with those of their metabolites.

Cancer Chemother Pharmacol. 1992;31(2):85-92. doi: 10.1007/BF00685092.

Characterization of two human mammary carcinomas, MT-1 and MT-3, suitable for in vivo testing of ether lipids and their derivatives.

Breast Cancer Res Treat. 1992;23(1-2):87-95. doi: 10.1007/BF01831480.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验